- Valeant (VRX) received an investigative subpoena from the California Department of Insurance in September following allegations that it forced customers to pay higher prices for its drugs.
- The request seeks materials including documents concerning Valeant's former relationship with Philidor, now defunct, and certain pharmacies responsible for the marketing and distribution of its products in California.
- SEC Form 10-Q